Replies to post #435707 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

They have never put out full data on anything so far.

100% on that. You just captured the essence of the reason for the extent of the share price decline. When a company massages the trial endpoints and has unreasonable delays in reporting out trial data, it creates the impression that data mining is taking place to paint a rosier outcome. What Missling has done is embolden the shorts/hedge funds. He has been promising additional trials now for years. He gets an F- on timeliness, without regard to whether or not EXCELLENCE turns out to be a home run.

[Investor2014]

Indeed, but Bas and a few others either don’t get it, won’t face reality or is in love with TGD and $AVXL.

[bas2020]

Investors are really sick of FUDsters saying that the data are inconclusive, suggesting the trials have failed. Just because FUDsters state claims of "cherry picking" or "moved goalposts" doesn't make it true.

Here again are the astonishing data of the P2b/3 AD trial, that met all endpoints and where patients functionally improved...

• Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% CI) 1.839 (1.17, 2.94) P = 0.015

• Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% CI) 2.67 (1.17, 6.13) P = 0.0255

• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• Mean difference in ADAS-Cog score change of -1.85 points

• Compared to placebo, ANAVEX®2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by CDR-SB

• ADCS-Cog and CDR-SB (p < .025) proving further significance of stat. sig. improvements and trial success.

• Identification of two key biomarkers (Aß42/40 ratio and brain volume stabilization) for AA pathway option.

For FUDsters to continually deny these results is plain false shenanigans with a nefarious motive.